Coya's central causal theory is that impaired regulatory T cell function contributes to chronic neuroinflammation in age-related neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease. If Tregs normally restrain harmful immune activation, then loss or dysfunction of Treg activity should permit inflammatory monocytes, macrophages, microglia, and effector T cell responses to accelerate neuronal injury and clinical decline.
A testable prediction is that patients with worse Treg dysfunction should show faster disease progression or more severe neuroinflammatory biomarkers, while interventions that restore Treg number or suppressive function should reduce inflammatory biomarkers and slow functional decline.
company website · Mon Jun 29 2026 05:45:28 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility7.0
The premise is biologically credible. Tregs normally restrain immune activation, and the evidence context links Treg dysfunction to ALS progression, regulatory immune impairment in untreated Parkinson's disease, and altered Treg profiles in Alzheimer's disease. The weak point is causality across diseases: ALS has the cleanest human correlation, while Alzheimer's and Parkinson's evidence looks broader and more mixed. Treg dysfunction may be one driver of neuroinflammation, but the provided evidence does not prove it is the initiating driver.
Supporting evidence: ALS patients are reported to have dysfunctional regulatory T lymphocytes, with dysfunction correlating with disease progression rate and severity.; Untreated Parkinson's disease shows regulatory immune impairment involving Tregs and other regulatory populations.; Regulatory T cell profile changes have been characterized in Alzheimer's disease.; The theory includes a coherent mechanism: impaired suppressive Treg activity permits monocytes, macrophages, microglia, and effector T cells to remain activated.
Counter evidence: Parkinson's disease evidence is not restricted to Tregs, which weakens a Treg-centered causal claim.; Alzheimer's disease evidence is described as profile changes consistent with immune dysregulation, which is weaker than direct causal evidence.; Measured Treg number, phenotype, or suppressive function is only a medium-confidence proxy for disease-relevant regulatory activity.
Explanatory power6.0
The theory explains a real pattern: worse regulatory immune control could plausibly track with higher neuroinflammatory biomarkers and faster decline. It fits ALS especially well because the provided evidence ties Treg dysfunction to progression rate and severity. But it does not yet beat alternative explanations cleanly. Neurodegeneration can itself disturb immune regulation, and microglial activation, protein aggregation, mitochondrial stress, vascular injury, and peripheral inflammation could all produce overlapping biomarker signals. The theory is useful, but it is not yet the boss of the evidence.
Supporting evidence: The ALS observation directly matches the prediction that worse Treg dysfunction should associate with faster progression.; Preclinical Parkinson's disease models show neuroprotective or anti-neuroinflammatory effects from Treg-enhancing or Treg-transfer approaches.; Preclinical Alzheimer's disease models show neuroprotective or neuroinflammation-modifying effects from Treg-based approaches.; The theory connects peripheral immune regulation to monocytes, macrophages, microglia, effector T cells, neuronal injury, and clinical decline.
Counter evidence: The evidence context does not show that Treg dysfunction precedes neurodegeneration in humans.; Several diseases are grouped together, but ALS, Alzheimer's disease, and Parkinson's disease have different initiating pathologies.; Alternative inflammatory mechanisms could explain the same observations without making Treg dysfunction the central causal driver.
Falsifiability8.0
The theory is testable. It predicts that patients with worse Treg dysfunction should have faster clinical decline or stronger neuroinflammatory biomarkers, and that restoring Treg number or suppressive function should reduce inflammatory biomarkers and slow functional decline. Those claims can fail in longitudinal cohorts and randomized intervention trials. The main caveat is measurement: if Treg phenotype, Treg suppressive assays, biomarkers, and clinical endpoints are noisy, a failed test could be blamed on the assay instead of the theory.
Supporting evidence: The theory states a directional patient-level prediction: worse Treg dysfunction should track with faster progression or more severe neuroinflammatory biomarkers.; The intervention prediction is concrete: Treg restoration should reduce inflammatory biomarkers and slow functional decline.; IL-2-based approaches and ex vivo expanded Tregs provide intervention routes that can test the mechanism.; The evidence context explicitly names biomarker and clinical progression measures as required readouts.
Counter evidence: The proxy problem is real: measured Treg number, phenotype, or suppressive function may not capture the regulatory activity relevant inside the nervous system.; Clinical progression measures in neurodegenerative disease can be variable and may require large or long trials to detect a causal effect.; If multiple regulatory immune populations change together, isolating Treg-specific falsification becomes harder.
Reasoning tree
premise
Impaired regulatory T cell function contributes causally to chronic neuroinflammation in age-related neurodegenerative diseases including ALS, Alzheimer's disease, and Parkinson's disease.
medium confidence - 5 linked evidence items
premise
assumes
Regulatory T cells normally restrain harmful immune activation in the nervous system and peripheral immune compartments.
high confidence - 3 linked evidence items
derivation
implies
Loss or dysfunction of Treg suppressive activity permits inflammatory monocytes, macrophages, microglia, and effector T cell responses to remain activated.
medium confidence - 3 linked evidence items
derivation
implies
Sustained inflammatory immune activation accelerates neuronal injury and clinical decline in neurodegenerative disease.
medium confidence - 3 linked evidence items
prediction
predicts
Patients with worse Treg dysfunction should show faster disease progression or more severe neuroinflammatory biomarkers.
high confidence - 2 linked evidence items
assumption
requires
Measured Treg number, phenotype, or suppressive function is a valid proxy for the disease-relevant regulatory immune activity driving neuroinflammation.
medium confidence - 2 linked evidence items
prediction
predicts
Interventions that restore Treg number or suppressive function should reduce inflammatory biomarkers and slow functional decline.
medium confidence - 3 linked evidence items
observation
observed_in
Treg-enhancing or Treg-transfer approaches show neuroprotective or anti-neuroinflammatory effects in preclinical Parkinson's disease models.
medium confidence - 2 linked evidence items
observation
observed_in
Treg-based approaches show neuroprotective or neuroinflammation-modifying effects in preclinical Alzheimer's disease models.
medium confidence - 2 linked evidence items
assumption
requires
Neuroinflammatory biomarkers and clinical progression measures are sensitive enough to detect causal effects of Treg restoration.
medium confidence - 3 linked evidence items
project_implication
implies
A therapeutic program should prioritize interventions that expand Tregs or enhance their suppressive function, such as IL-2-based approaches or ex vivo expanded Tregs.
medium confidence - 3 linked evidence items
observation
observed_in
ALS patients have dysfunctional regulatory T lymphocytes, and the dysfunction correlates with disease progression rate and severity.
high confidence - 1 linked evidence item
observation
observed_in
Untreated Parkinson's disease shows regulatory immune impairment involving Tregs and other regulatory populations.
medium confidence - 1 linked evidence item
observation
observed_in
Regulatory T cell profile changes have been characterized in Alzheimer's disease, consistent with immune dysregulation in neurodegeneration.
medium confidence - 2 linked evidence items
Public endorsements
silent
The dossier ties Anabella Villalobos to Coya through a 2021 board appointment and describes her broader drug-discovery leadership, but it does not show a public statement from her endorsing, discussing, or disputing Coya's theory that Treg dysfunction drives neuroinflammatory neurodegeneration.
mentions
Arun Swaminathan publicly ties Coya to "Treg-targeted therapies" across ALS, FTD, Parkinson's, and Alzheimer's, and he frames the company's science as part of its investor case. That is a public mention of the Treg-centered program. The evidence here does not show him explicitly stating the full causal theory that Treg dysfunction drives neuroinflammatory neurodegeneration, so "publicly_endorses" would go too far.
mentions
Arun Swaminathan is publicly tied to Coya's Treg-based neurodegeneration program in a September 4, 2025 Q&A titled "Targeting Neurodegenerative Diseases Through Treg Therapies." That is a public mention of the theory area, but the provided evidence does not include a direct statement from him endorsing the full causal claim that Treg dysfunction drives neuroinflammatory neurodegeneration.
Berman publicly ties Coya to Treg-based therapies and neurodegenerative disease, and he explicitly praised Treg-derived exosomes as an immunosuppression approach. That is directionally aligned with the theory. The evidence here does not show him plainly stating the full causal claim that Treg dysfunction drives neuroinflammatory neurodegeneration, so this is a mention rather than a clean public endorsement.
Adoptive or ex vivo restored Tregs can directly protect neurons
Coya's inclusion of Treg cell therapy implies a causal theory that dysfunctional patient Tregs can be restored or replaced to recover suppressive, neuroprotective activity. The supplied publications describe ex vivo expansion restoring Treg suppressive function and Treg-based approaches reducing neuroinflammation in preclinical neurodegenerative disease models.
A testable prediction is that expanded or adoptively transferred Tregs should show restored suppressive function, reduce neuroinflammatory pathology, and protect neurons or delay functional decline in disease models and eventually in patients.
company website · Mon Jun 29 2026 05:45:28 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility7.0
The premise is credible: patient Tregs can be dysfunctional in ALS, Parkinson's disease, and Alzheimer's contexts, and multiple cited models link Treg activity to lower neuroinflammation and neuronal protection. The weak point is the word "directly." The evidence supports immune suppression and reduced inflammatory damage; it does not yet prove that transferred or expanded Tregs protect neurons through a neuron-facing mechanism rather than by changing the inflammatory environment around them.
Supporting evidence: ALS patients' regulatory T lymphocytes are reported as dysfunctional and correlated with disease progression rate and severity.; Treg-based approaches reduced neuroinflammation and protected neurons in Parkinson's disease mouse models.; Ex vivo expanded human regulatory T cells modified neuroinflammation in a preclinical Alzheimer's disease model.
Counter evidence: The evidence context is mostly preclinical for neuronal protection.; The causal chain from restored suppressive function to durable patient-level functional benefit remains assumed.; Parkinson's disease immune impairment is described as broader than Tregs alone, which weakens a Treg-only explanation.
Explanatory power6.0
Dual IL-2 and abatacept immunomodulation slows ALS progression
For COYA 302, the specific causal theory is that low-dose interleukin-2 enhances anti-inflammatory regulatory T cells while DRL_AB, an abatacept biosimilar candidate, suppresses inflammation from activated monocytes and macrophages. Together, the combination is intended to rebalance immune dysfunction in ALS more effectively than Treg stimulation alone.
The ALSTARS Phase 2 trial tests whether this dual immunomodulatory mechanism improves ALS clinical and biological outcomes, including ALSFRS-R decline, neurofilament, respiratory and neurological measures, inflammatory biomarkers, and safety versus placebo.
company website · Mon Jun 29 2026 05:45:28 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility6.0
The biological base is credible: ALS has documented immune dysregulation, Tregs correlate with progression rate and severity, and low-dose IL-2 can expand Tregs. The weak point is DRL_AB. The dossier gives no direct ALS evidence that this abatacept biosimilar candidate suppresses activated monocyte and macrophage inflammation at a level that changes disease course. So the theory starts from real immunology, then asks one extra mechanism to carry a lot of weight.
Supporting evidence: ALS patients' regulatory T lymphocytes are reported as dysfunctional and correlated with disease progression rate and severity.; Low-dose interleukin-2 is supported as a way to enhance or expand anti-inflammatory regulatory T cells.; Immune dysfunction and neuroinflammation are listed as contributors to ALS progression.
Counter evidence: The DRL_AB mechanism in ALS is marked as a low-confidence assumption with no supporting publication IDs in the provided evidence.; The theory assumes that targeting Tregs and innate inflammatory activation together will outperform Treg stimulation alone, but the evidence provided does not yet show that combination effect in ALS patients.
Explanatory power5.0
Treg enhancement restores immune homeostasis
Coya's platform theory is that enhancing regulatory T cell function can restore immune homeostasis and thereby modify diseases of aging where chronic inflammation contributes to tissue damage. The company applies this mechanism across neurodegenerative, autoimmune, and metabolic diseases using Treg-enhancing biologics, Treg-derived exosomes, and Treg cell therapy.
The prediction is that therapies increasing Treg activity should produce measurable anti-inflammatory effects, improve disease-relevant biomarkers, and translate into slower progression or improved function in age-related disease settings such as ALS and Alzheimer's disease.
company website · Mon Jun 29 2026 05:45:28 GMT+0000 (Coordinated Universal Time) · Source
Popperian evaluation
Premise plausibility7.0
The core biology is credible: Tregs suppress excessive immune activation, and the evidence context links Treg dysfunction or immune dysregulation to ALS, Alzheimer's disease, Parkinson's disease, and broader neuroinflammatory damage. The weaker step is the jump from disease association to restoration. A low or dysfunctional Treg signal can mark disease biology without being the control point that reverses it.
Supporting evidence: Regulatory T cells normally suppress excessive immune activation and help maintain immune homeostasis.; In ALS, regulatory T lymphocytes are dysfunctional and correlate with disease progression rate and severity.; In Alzheimer's disease, immune dysregulation and neuroinflammatory changes are implicated in disease biology.
Counter evidence: The evidence context gives stronger support for association than for causal rescue in human age-related disease.; The platform assumes biologics, Treg-derived exosomes, and Treg cell therapy can raise Treg activity safely and enough to matter, but that assumption is only medium confidence.; Shared applicability across neurodegenerative, autoimmune, and metabolic diseases rests on a low-confidence assumption.
Explanatory power
silent
The record shows Mark Pavao is publicly listed in connection with Coya, and a separate quote shows him discussing an investment in 4M Therapeutics, not Coya's Treg dysfunction theory in neurodegeneration. In the evidence provided here, he does not publicly endorse, describe, or dispute Coya's causal claim about impaired Treg function driving neuroinflammatory neurodegeneration.
The theory explains a real pattern: dysfunctional Tregs track with worse disease, and restoring or adding suppressive Tregs can reduce neuroinflammatory pathology in models. That is a coherent account. But alternative explanations remain live. Benefits could come from broad immune recalibration, IL-2 effects on several immune compartments, model-specific inflammation, or downstream cytokine shifts rather than restored Tregs acting as the decisive protective agent.
Supporting evidence: Regulatory T cells have suppressive immune functions that can restrain neuroinflammation in nervous system disease contexts.; Adoptive Treg approaches showed neuroprotective effects in Parkinson's and Alzheimer's disease models.; IL-2-based enhancement expands neuroprotective regulatory T cells, supporting the idea that Treg number or function can be increased therapeutically.
Counter evidence: The evidence does not rule out non-Treg immune mechanisms as the main driver of benefit.; Preclinical neurodegeneration models often overstate translation to human disease.; Reduced neuroinflammation may be helpful without being sufficient to delay clinical decline.
Falsifiability8.0
This theory is readily testable. Expanded or transferred Tregs should regain suppressive function, reduce defined neuroinflammatory markers, preserve neurons, and slow functional decline against untreated or dysfunctional-Treg controls. A clean failure on those linked endpoints would damage the theory, especially if the transferred cells survive and still fail to change pathology.
Supporting evidence: The theory predicts restored suppressive function compared with dysfunctional patient Tregs or untreated disease controls.; It predicts reduced neuroinflammatory pathology in disease models.; It predicts neuronal protection or delayed functional decline in models and eventually in patients.
Counter evidence: Clinical falsification will be slower because neurodegenerative outcomes need enough follow-up time and well-chosen endpoints.; If trials only measure immune biomarkers, the neuron-protection claim can escape a hard test.
Reasoning tree
derivation
Adoptive or ex vivo restored regulatory T cells can directly protect neurons by restoring suppressive immune function and reducing neuroinflammatory pathology.
medium confidence - 3 linked evidence items
premise
implies
Patient regulatory T cells can be dysfunctional in neurodegenerative disease, and this dysfunction is associated with disease progression or severity.
medium confidence - 3 linked evidence items
premise
implies
Regulatory T cells have suppressive immune functions that can restrain neuroinflammation in nervous system and neurodegenerative disease contexts.
medium confidence - 5 linked evidence items
observation
observed_in
Treg-based approaches have reduced neuroinflammation and protected neurons in preclinical Parkinson's disease models.
medium confidence - 2 linked evidence items
observation
observed_in
Treg-based approaches have shown neuroprotective effects in preclinical Alzheimer's disease models.
medium confidence - 2 linked evidence items
premise
requires
Ex vivo expansion can restore or enhance regulatory T-cell suppressive function sufficiently to make them usable as a therapeutic cell product.
medium confidence - 2 linked evidence items
premise
implies
IL-2-based enhancement can expand neuroprotective regulatory T cells, supporting the broader idea that Treg number or function can be therapeutically increased.
medium confidence - 2 linked evidence items
assumption
assumes
Restored or replacement Tregs retain suppressive and neuroprotective activity after transfer into the disease environment.
medium confidence - 3 linked evidence items
assumption
assumes
Reducing neuroinflammatory pathology is causally sufficient to protect neurons or delay functional decline in relevant neurodegenerative disease settings.
medium confidence - 4 linked evidence items
prediction
predicts
Expanded or adoptively transferred Tregs should show restored suppressive function compared with dysfunctional patient Tregs or untreated disease controls.
high confidence - 2 linked evidence items
prediction
predicts
Expanded or adoptively transferred Tregs should reduce neuroinflammatory pathology in disease models.
high confidence - 3 linked evidence items
prediction
predicts
Expanded or adoptively transferred Tregs should protect neurons or delay functional decline in neurodegenerative disease models and eventually in patients.
medium confidence - 3 linked evidence items
project_implication
implies
Coya's inclusion of Treg cell therapy implies a development rationale centered on restoring or replacing dysfunctional patient Tregs to recover suppressive, neuroprotective activity.
The evidence shows Villalobos joined Coya's board and has broad drug-discovery and neuroscience credentials, but it does not show a public statement from her endorsing, describing, or disputing Coya's theory that restored or adoptively transferred Tregs can directly protect neurons.
Swaminathan publicly talks up Coya's science, says the company believes stopping neurodegenerative disease progression is possible, and discusses Coya's "Treg-targeted therapies" across ALS, FTD, Parkinson's, and Alzheimer's. That is consistent with the theory, but the supplied quotes do not explicitly state the narrower mechanistic claim that adoptively transferred or ex vivo restored Tregs directly protect neurons.
Arun Swaminathan publicly discusses Coya's neurodegenerative disease program in connection with Treg therapies, which is consistent with the company theory. But the supplied evidence does not give a direct quote from him endorsing the specific causal claim that restored or adoptively transferred Tregs directly protect neurons by recovering suppressive function. On this record, he clearly mentions the approach, and may support it as CEO, but the evidence shown here is not specific enough to score as a direct public endorsement of that exact theory.
Berman speaks publicly about Coya's Treg-based approach in neurodegenerative disease and, more specifically, says Treg-derived exosomes are "the future of immunosuppression for many indications." That is directionally aligned with Coya's immune-regulation thesis, but this dossier does not show him directly claiming that adoptively transferred or ex vivo restored Tregs protect neurons or restore neuroprotective function in patients.
silent
The supplied evidence places Mark Pavao as Managing Partner or Managing Director of Biotech Value Advisors and shows him listed on Coya's About Us page, but it does not give any public statement from him about Coya's theory that restored or adoptively transferred Tregs can protect neurons. The only quote provided is about his investment experience in 4M Therapeutics, which is unrelated to Treg-mediated neuroprotection.
The theory explains why a dual immune therapy might affect ALS biology: deficient regulatory control and excessive innate immune activation could both push neuroinflammation. That is coherent. It does less well at explaining existing clinical evidence, because the key ALSTARS outcomes are still predictions rather than observed results here. Alternative explanations remain open, including that immune abnormalities track disease severity without driving enough of the disease to change ALSFRS-R decline.
Supporting evidence: The evidence map links Treg dysfunction, innate immune activation, and ALS-associated neuroinflammation into one causal chain.; The theory predicts changes across clinical function, neurofilament, respiratory and neurological measures, inflammatory biomarkers, and safety, which matches the proposed mechanism.
Counter evidence: No provided ALSTARS efficacy results show that COYA 302 slows ALSFRS-R decline versus placebo.; Correlation between Treg dysfunction and ALS severity does not prove that correcting Tregs changes progression.; The added value over Treg stimulation alone is asserted, but no head-to-head evidence is provided.
Falsifiability8.0
This is the strongest Popperian feature. The theory makes plain bets: COYA 302 should slow ALSFRS-R decline, stabilize or improve neurofilament and inflammatory biomarkers, preserve respiratory and neurological measures, and remain acceptably safe versus placebo. A placebo-controlled Phase 2 trial can break the theory cleanly if the clinical endpoint fails and the biomarker pattern does not move in the immune direction claimed.
Supporting evidence: ALSTARS is described as testing COYA 302 versus placebo.; The stated readouts include ALSFRS-R decline, neurofilament, respiratory and neurological measures, inflammatory biomarkers, and safety.; The predictions specify clinical and biological outcomes rather than only subjective improvement.
Counter evidence: The dossier does not provide numeric success thresholds for ALSFRS-R, neurofilament, or inflammatory biomarkers.; Without a COYA 302 arm compared directly with low-dose IL-2 alone, the claim of superiority over Treg stimulation alone is harder to falsify in one trial.
Reasoning tree
project_implication
Dual immunomodulation with COYA 302 is expected to slow ALS progression more effectively than regulatory T-cell stimulation alone.
medium confidence - 2 linked evidence items
premise
requires
Immune dysfunction and neuroinflammation contribute to ALS progression.
medium confidence - 2 linked evidence items
premise
implies
Regulatory T cells are involved in nervous system immune regulation and neurodegenerative disease biology.
medium confidence - 3 linked evidence items
observation
observed_in
ALS patients' regulatory T lymphocytes are dysfunctional and correlate with disease progression rate and severity.
high confidence - 1 linked evidence item
premise
requires
Low-dose interleukin-2 can enhance or expand anti-inflammatory regulatory T cells.
medium confidence - 2 linked evidence items
derivation
implies
Enhancing regulatory T cells with low-dose interleukin-2 may reduce inflammatory immune activity relevant to neurodegeneration.
medium confidence - 4 linked evidence items
premise
requires
Activated monocytes and macrophages can contribute to inflammatory pathology in ALS.
medium confidence - 1 linked evidence item
assumption
assumes
DRL_AB, as an abatacept biosimilar candidate, suppresses inflammation from activated monocytes and macrophages in a way that is therapeutically relevant to ALS.
low confidence
derivation
implies
Combining low-dose interleukin-2 with DRL_AB targets both deficient regulatory immune control and excessive innate inflammatory activation.
medium confidence - 3 linked evidence items
derivation
implies
Targeting two immune mechanisms is expected to rebalance ALS-associated immune dysfunction more effectively than Treg stimulation alone.
medium confidence - 2 linked evidence items
prediction
predicts
In the ALSTARS Phase 2 trial, COYA 302 should slow ALSFRS-R decline versus placebo if the dual immunomodulatory mechanism is clinically effective.
medium confidence
assumption
assumes
Changes in ALSFRS-R decline, neurofilament, respiratory and neurological measures, inflammatory biomarkers, and safety are adequate readouts for testing whether COYA 302's immune mechanism benefits ALS patients.
medium confidence - 1 linked evidence item
prediction
predicts
COYA 302 should improve or stabilize biological markers of ALS activity, including neurofilament and inflammatory biomarkers, versus placebo.
medium confidence
prediction
predicts
COYA 302 should improve or stabilize respiratory and neurological measures versus placebo.
medium confidence
prediction
predicts
COYA 302 should demonstrate an acceptable safety profile in ALS patients compared with placebo.
The public evidence here shows that Coya appointed Anabella Villalobos to its board in May 2021. It does not show any statement from her about COYA 302, dual IL-2 plus abatacept immunomodulation, ALS, or the claimed mechanism, so she stays silent on this theory in the provided record.
Arun Swaminathan publicly talks about Coya's science, its goal of slowing or stopping neurodegenerative disease progression, and the company's Treg-targeted programs. That is directionally consistent with the COYA 302 immunomodulation theory, but the supplied evidence does not show him explicitly laying out the specific dual IL-2 plus abatacept mechanism or directly endorsing that causal claim in public.
Arun Swaminathan appears to discuss Coya's Treg-based neurodegeneration program publicly, including a 2025 Q&A explicitly about Treg therapies and a 2024 corporate update on COYA 302. The supplied evidence does not show a direct statement from him endorsing the full dual IL-2 plus abatacept mechanism in ALS, but it does show public discussion of the program.
Berman publicly ties Coya to multi-pathway therapies for ALS and is described in company media as leading work on COYA 302 and regulatory T cell-based treatments. That is a real public mention of the program area, but the evidence here does not show him explicitly endorsing the specific dual IL-2 plus abatacept mechanism or the claim that it slows ALS progression.
The provided evidence places Mark Pavao in Coya's orbit and identifies him as Managing Partner or Managing Director of Biotech Value Advisors, but it does not show him publicly discussing COYA 302, low-dose IL-2, abatacept, Treg expansion, monocyte or macrophage suppression, or the ALS trial theory. On this record, he stays silent on the theory itself.
The theory explains why anti-inflammatory and Treg-linked findings cluster across several aging diseases. It is less strong as a full disease explanation. ALS, Alzheimer's disease, Parkinson's disease, autoimmune disease, and metabolic disease have different upstream drivers, and inflammation may be a contributor, an amplifier, or a consequence depending on the setting. The theory earns a middle score because it organizes part of the evidence, but it does not yet beat disease-specific explanations.
Supporting evidence: Chronic inflammation contributes to tissue damage in neurodegenerative, autoimmune, and metabolic diseases associated with aging.; In Parkinson's disease models and patients, regulatory immune impairment or Treg activity is linked to neuroinflammation and neuroprotection.; If Treg dysfunction contributes to inflammatory pathology, therapies that increase Treg activity should reduce pathological inflammation.
Counter evidence: The evidence context does not show that Treg dysfunction is upstream of disease progression across all target indications.; Alzheimer's disease evidence is described as immune dysregulation and neuroinflammatory changes, which leaves room for amyloid, tau, vascular, metabolic, or glial-first explanations.; The broad platform claim depends on shared inflammatory and Treg-related mechanisms across disease categories, and that node has low confidence.
Falsifiability8.0
This theory is testable. It predicts that raising Treg activity should reduce inflammatory markers, improve disease-relevant biomarkers, and slow progression or improve function in ALS and Alzheimer's disease. A clean failure pattern would hurt the theory: confirmed Treg enhancement with no anti-inflammatory effect, no biomarker movement, and no clinical signal. The main weakness is that the current prediction wording lacks exact thresholds, time windows, and endpoints.
Supporting evidence: Therapies increasing Treg activity should produce measurable anti-inflammatory effects.; Therapies increasing Treg activity should improve disease-relevant biomarkers in age-related inflammatory disease settings.; Therapies increasing Treg activity should translate into slower progression or improved function in age-related diseases such as ALS and Alzheimer's disease.
Counter evidence: The predictions are directionally clear but do not define exact biomarker thresholds, clinical endpoints, or minimum effect sizes.; Different modalities, including biologics, exosomes, and cell therapy, could fail for delivery or dosing reasons while leaving the broad Treg hypothesis partly protected.; The theory could become too flexible if any anti-inflammatory movement is treated as support without a disease-relevant functional effect.
Reasoning tree
premise
Enhancing regulatory T cell function can restore immune homeostasis in diseases of aging where chronic inflammation contributes to tissue damage.
medium confidence - 3 linked evidence items
premise
assumes
Regulatory T cells normally suppress excessive immune activation and help maintain immune homeostasis.
high confidence - 2 linked evidence items
premise
assumes
Chronic inflammation contributes to tissue damage in neurodegenerative, autoimmune, and metabolic diseases associated with aging.
medium confidence - 3 linked evidence items
observation
observed_in
In ALS, regulatory T lymphocytes are dysfunctional and correlate with disease progression rate and severity.
high confidence - 2 linked evidence items
observation
observed_in
In Alzheimer's disease, immune dysregulation and neuroinflammatory changes are implicated in disease biology.
medium confidence - 4 linked evidence items
observation
observed_in
In Parkinson's disease models and patients, regulatory immune impairment or Treg activity is linked to neuroinflammation and neuroprotection.
medium confidence - 4 linked evidence items
derivation
implies
If Treg dysfunction contributes to inflammatory pathology, then therapies that increase Treg activity should reduce pathological inflammation.
medium confidence - 3 linked evidence items
assumption
requires
Treg enhancement can be achieved safely and sufficiently through biologics, Treg-derived exosomes, or Treg cell therapy.
medium confidence - 2 linked evidence items
derivation
implies
Restoring immune homeostasis through enhanced Treg activity should modify disease biology rather than only suppress symptoms.
medium confidence - 3 linked evidence items
prediction
predicts
Therapies increasing Treg activity should produce measurable anti-inflammatory effects.
medium confidence - 3 linked evidence items
prediction
predicts
Therapies increasing Treg activity should improve disease-relevant biomarkers in age-related inflammatory disease settings.
medium confidence - 3 linked evidence items
prediction
predicts
Therapies increasing Treg activity should translate into slower progression or improved function in age-related diseases such as ALS and Alzheimer's disease.
medium confidence - 4 linked evidence items
project_implication
implies
Coya can apply a shared Treg-enhancement platform across neurodegenerative, autoimmune, and metabolic diseases where chronic inflammation is disease-relevant.
medium confidence - 3 linked evidence items
assumption
requires
Inflammatory and Treg-related mechanisms are sufficiently shared across these disease categories for one platform mechanism to be broadly applicable.
The public evidence here shows that Anabella Villalobos joined Coya's board in May 2021, and that Coya described itself as developing Treg and Treg-derived exosome therapies. It does not show Villalobos herself publicly endorsing, explaining, or disputing the theory that Treg enhancement restores immune homeostasis. Board membership is real evidence of involvement, but it is not a public statement of support for this specific mechanism.
Arun Swaminathan publicly backs the theory. He frames Coya's case around "the science" with early evidence and validating partnerships, and he is quoted promoting Coya's "Treg-targeted therapies" across ALS, FTD, Parkinson's, and Alzheimer's. The claim that Coya believes stopping progression is possible in neurodegenerative disease also fits the theory that boosting Treg function can change disease course, not just describe the platform.
Arun Swaminathan is identified in the evidence as Coya's CEO, and a September 4, 2025 public Q&A is specifically framed around "targeting neurodegenerative diseases through Treg therapies," which aligns directly with the theory that boosting Treg function can modify inflammatory age-related disease. The November 6, 2024 corporate update also places him as the public executive voice for Coya's pipeline progress. We do not have a direct quote here, so the judgment rests on the public framing of his CEO communications rather than a verbatim statement.
Berman publicly aligns himself with Coya's Treg-centered theory. He said, "Treg derived exosomes represent the future of immunosuppression for many indications," and company posts describe him discussing Coya's therapies for ALS, Alzheimer's, and other aging-related conditions. A later company publication also ties him to Coya's work on therapies that enhance regulatory T cells across neurodegenerative, autoimmune, and metabolic disease.
The record shows Mark Pavao listed on Coya Therapeutics' About Us page as Managing Director of Biotech Value Advisors, which supports that he is publicly associated with the company. It does not show him endorsing, describing, or disputing Coya's theory that Treg enhancement restores immune homeostasis. The only direct quote in the evidence is about a different company, 4M Therapeutics.
